Protocol Ledger

NCT03467152 · Phase II · COMPLETED

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Interventional Phase II clinical trial protocol NCT03467152 sponsored by Eisai in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-04 Enrollment: 326 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03467152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)326 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03467152
Protocol FieldVerified Registry Value
NCT IdentifierNCT03467152
Consolidated Lead SponsorEisai
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment326 participants (ACTUAL)
Registered Start Date2018-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03467152
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->
Syrentis Clinical ResearchSanta Ana, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI